% | $
Quotes you view appear here for quick access.

Roche Holding AG Message Board

  • rybovich58 rybovich58 Jun 13, 2011 3:10 PM Flag

    Buyout Target

    Vical Incorporated (VICL). Vical researches and develops vaccine therapies for the prevention and treatment of cancer and other infectious diseases, with five active clinical and preclinical programs in development. Vical share prices have been fluctuating around $3.74 at the time of writing.
    We're high on Vical's prospects because of its use of DNA vaccines, which offer less risk and more efficient manufacturing compared to traditional pathogen-induced vaccines. The technology allows Vical to provide vaccines in weeks instead of months or years without ever having to handle the pathogen.

    Based on Vical's effective products in the pipeline, lack of debt, and reserves of cash to last it through 2012, we see Vical as a strong buy. We think shares could reach closer to $5 by year's end with initiation of Phase III trials for multiple drugs.

    We think Roche (RHHBY.PK) or Novartis vaccine divisions might be interested in Vical's treatment platforms.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
30.98+0.03(+0.10%)Aug 30 3:58 PMEDT